The partnership will help Kaia Health to accelerate sales growth in the U.S. healthcare market, extend its platform into other chronic indications and expand the supporting clinical evidence base.
Balderton previously led the firm's Series A in January 2019.
Kaia Health has developed a smartphone-based approach for managing a range of chronic conditions, with its leading product focused on musculoskeletal disorders, such as chronic back pain.
Its motion tracking technology enables users to get real-time feedback on their exercise performance using their smartphone’s camera, which, when combined with the app’s psychological and education support, has been proven to outperform conventional therapy.
The company already has three peer-reviewed clinical studies, including a randomised controlled trial recently published in NPJ Digital Medicine, and has additional clinical studies ongoing in the United States.
Read more:
Sign up for our newsletter to stay up to date on news from Balderton, and our portfolio.
The Stables
28 Britannia street
London WC1X 9JF UK
+44 (0) 20 7016 6800
+44 (0) 20 7016 6810
